SCHEMBL11932079

SCHEMBL11932079

CCOC(=O)C(c1ccc([N+](=O)[O-])cc1)C1CCCC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 5/20 0.54
ALDH1A1 P00352 3/20 0.54
GAA P10253 1/20 0.54
MAPT P10636 4/20 0.51
SMN1; SMN2 Q16637 2/20 0.48
POLB P06746 1/20 0.48
LMNA P02545 3/20 0.48
KDM4E B2RXH2 1/20 0.48
SLC6A2 P23975 4/20 0.47
CYP3A4 P08684 2/20 0.47
CHRM2 P08172 1/20 0.47
HTR1A P08908 1/20 0.47
ADRA2A P08913 1/20 0.47
CHRM1 P11229 1/20 0.47
DRD1 P21728 1/20 0.47
ADRA1A P35348 1/20 0.47
OPRM1 P35372 1/20 0.47
DRD3 P35462 1/20 0.47
KCNH2 Q12809 1/20 0.47
CYP1A2 P05177 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13114880 0.82 MAPT (0.65) ALDH1A1GAAMAPTSMN1; SMN2POLB
SCHEMBL11932077 0.81 SLC6A3 (0.51) SLC6A3GAAPOLBLMNASLC6A2
SCHEMBL28632940 0.80 SLC6A2 (0.67) SLC6A3MAPTLMNASLC6A2CYP3A4
SCHEMBL1565892 0.80 SLC6A3 (0.51) SLC6A3GAAMAPTPOLBLMNA
SCHEMBL287297 0.80 SLC6A3 (0.46) SLC6A3ALDH1A1MAPTSMN1; SMN2POLB
SCHEMBL1418921 0.80 ALDH1A1 (0.49) SLC6A3ALDH1A1GAAMAPTSMN1; SMN2
SCHEMBL10955574 0.79 SLC6A2 (0.70) SLC6A3MAPTSMN1; SMN2LMNASLC6A2
SCHEMBL4279296 0.77 MAPT (0.57) ALDH1A1GAAMAPTSMN1; SMN2LMNA
SCHEMBL10771702 0.77 MAPT (0.57) ALDH1A1GAAMAPTSMN1; SMN2LMNA
SCHEMBL27482391 0.76 SLC6A3 (0.48) SLC6A3ALDH1A1GAAMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2649045-B1 SUBSTITUTED 1-BENZYLCYCLOALKYLCARBOXLIC ACIDS AND USE THEREOF BAYER IP GMBH (DE) 2015-05-27 EP disclosed
US-9018258-B2 Substituted 1-benzylcycloalkylcarboxylic acids and the use thereof BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-04-28 US disclosed
US-9018258-B2 Substituted 1-benzylcycloalkylcarboxylic acids and the use thereof BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-04-28 US disclosed
US-20120172448-A1 Substituted 1-benzylcycloalkylcarboxylic acids and the use thereof BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-07-05 US disclosed
US-20120172448-A1 Substituted 1-benzylcycloalkylcarboxylic acids and the use thereof BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172448-A1 Substituted 1-benzylcycloalkylcarboxylic acids and the use thereof PC, ACACA, PCCA SLC6A3 3041/4885ALDH1A1 419/4885GAA 271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.